Peder K. Jensen

Peder K. Jensen, M.D., has been a member of Acorda’s Board of Directors since April 2011. Dr. Jensen is currently President of Bay Way Consultants LLC, a consulting firm he founded in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen’s experience includes more than 20 years with global pharmaceutical company Schering-Plough, and then Merck & Co., Inc. following the merger of the two companies in 2009. During his tenure at Schering-Plough/Merck, Dr. Jensen held a number of global senior research and development positions, including Vice President Clinical Research, SPRI, Executive Vice President Worldwide Drug Development, SPRI, and most recently Corporate Senior Vice President, and General Manager, Resource & Development for Japan and Asia/Pacific from 2006 to 2010.

Dr. Jensen has more than 25 years of global drug development experience across a variety of therapeutic areas, including neurology, cardiovascular, anti-infective, oncology and immunology. Over the course of his career, Dr. Jensen has been responsible for more than 40 new drug approvals in the U.S., Europe and Japan. He currently serves on the Board of Directors of FivePrime Therapeutics, Inc.